Cetuximab is an EGFR-targeted chimeric monoclonal antibody oncology therapy marketed as Erbitux. It is used in metastatic colorectal cancer and head and neck cancers, with biomarker selection in colorectal use. It is administered via intravenous infusion and is prescription-only.
Phase 3 BREAKWATER trial shows encorafenib plus cetuximab and chemotherapy achieved 30.3 months median overall survival versus 15.1 months with standard therapy in previously untreated BRAF V600E-mutant metastatic colorectal cancer.
Pfizer announced positive progression-free survival results from the BREAKWATER trial evaluating Braftovi in combination with cetuximab and Folfiri in previously untreated metastatic colorectal cancer patients with BRAF V600E mutation.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05745857 |
Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas |
RECRUITING | PHASE2 |
| NCT01794845 |
Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma |
TERMINATED | PHASE2 |
| NCT01237483 |
Reirradiation and Erbitux in the HNSCC |
COMPLETED | PHASE2 |
| NCT01102231 |
Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) |
COMPLETED | PHASE2 |
| NCT00681876 |
Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer |
TERMINATED | PHASE2 |
| NCT00570674 |
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck |
TERMINATED | PHASE1/PHASE2 |
| NCT00518193 |
Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix |
TERMINATED | PHASE2 |
